{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
deoxycholic acid
to a specific field?
Status:
US Previously Marketed
Source:
ARFONAD by ROCHE
(1954)
Source URL:
First approved in 1954
Source:
ARFONAD by ROCHE
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Trimethaphan (or Trimethaphan camsylate), a ganglionic blocking agent and an antihypertensive drug, was marketed under the brand name Arfonad. Arfonad is indicated to induce systemic arterial hypotension in patients undergoing major surgery and to treat severe systemic hypertension, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension. Trimethaphan prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. This drug was discontinued because of the competition from newer drugs that are more selective in their actions and effects.
Status:
US Previously Marketed
Source:
ANSOLYSEN by WYETH AYERST
(1961)
Source URL:
First approved in 1954
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves.
Status:
US Previously Marketed
Source:
CYSTOKON by MALLINCKRODT
(1961)
Source URL:
First approved in 1953
Source:
SALPIX by ORTHO MCNEIL PHARM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Acetrizoic acid (trade names Gastrografina, Urografina in Portugal) is a palatable lemon-flavored water-soluble iodinated radiopaque X-ray contrast medium for oral or rectal administration only. Acetrizoic acid is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine.
Status:
US Previously Marketed
First approved in 1953
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Ethopropazine is an anticholinergic drug. Ethopropazine is an inhibitor of butyrylcholinesterase and non-selective muscarinic acetylcholine receptor antagonist. Ethopropazine has been used for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also It used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Status:
US Previously Marketed
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Protoveratrine A, the principal alkaloid of Veratrum album, has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Status:
US Previously Marketed
Source:
VIOCIN SULFATE by PFIZER
(1961)
Source URL:
First approved in 1953
Source:
VIOCIN SULFATE by PFIZER
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Viomycin is a basic peptide antibiotic, which is among the most effective agents against multidrug-resistant tuberculosis. The tuberactinomycins, such as Viomycin, target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. Specifically, viomycin binds to a site on the ribosome which lies at the interface between helix 44 of the small ribosomal subunit and helix 69 of the large ribosomal subunit. The structures of this complexes suggest that the viomycin inhibits translocation by stabilizing the tRNA in the A site in the pretranslocation state.
Status:
US Previously Marketed
Source:
CENTRINE/PHENOBARBITAL AMINOPENTAMIDE HYDROGEN SULFATE by BRISTOL LABS
(1961)
Source URL:
First approved in 1953
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Aminopentamide is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine. Aminopentamide hydrogen sulfate is marketed under the brand name Centrine indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea of the dogs and cats. Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine. Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility. Aminopentamide is a nonselective muscarinic cholinergic .
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ferrocholinate is a chelate prepared by reacting equal quantities of freshly precipitated ferric chloride with choline dihydrogen citrate. Ferrocholinate is used as a source of iron in iron deficiency anemia. Ferrocholinate absorption is increased by simultaneous administration of ascorbic acid. Absorption reduced by antacids, cholestyramine or proton pump inhibitors (omeprazole, pantoprazole, lansoprazole). The following adverse effects may occur: occasionally, gastrointestinal disorders (stomach pain, nausea, constipation or diarrhea) may appear, which usually disappear quickly after the dose is reduced or, if necessary, after treatment discontinuation. Darkness of stool: it is frequently observed during treatment and is safe for the patient. Allergic reactions may occur, also.
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ACHIRAL)
CALCIUM CYCLAMATE, a salt of cyclamic acid, is an artificial sweetener. Cyclamates and its salts (such as calcium cyclamate, sodium cyclamate, magnesium cyclamate, and potassium cyclamate) are currently prohibited from use in the United States.
